FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
-
Published:2019-07
Issue:
Volume:115
Page:97-106
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Malka David, François Eric, Penault-Llorca Frédérique, Castan Florence, Bouché Olivier, Bennouna Jaafar, Ghiringhelli François, de la Fouchardière Christelle, Borg Christophe, Samalin Emmanuelle, Bachet Jean-BaptisteORCID, Raoul Jean-Luc, Miglianico Laurent, Bengrine-Lefèvre Leila, Dahan Laetitia, Lecaille Cédric, Aparicio Thomas, Stanbury Trevor, Perrier Hervé, Cayre Anne, Laurent-Puig Pierre, Gourgou Sophie, Emile Jean-François, Taïeb Julien
Subject
Cancer Research,Oncology
Reference35 articles.
1. WHO International Agency for Research on Cancer. Cancer fact sheets. http://gco.iarc.fr (accessed December 12, 2018). 2. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Smyth;Ann Oncol,2016 3. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial;Waddell;Lancet Oncol,2013 4. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial;Lordick;Lancet Oncol,2013 5. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial;Catenacci;Lancet Oncol,2017
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|